RCUS - Surface Oncology's lead cancer programs to advance to combination and expansion stages of early-stage studies

Surface Oncology (SURF) has announced that both of its lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), have achieved predefined criteria for advancement into combination and expansion stages of ongoing Phase 1 trials.Phase 1/1b trial of SRF617 was initiated in March for solid tumors and is currently enrolling patients. Summary results from nine patients treated across three dose levels show increased target occupancy on B cells in a dose-dependent manner, and within the 200mg cohort. Prolonged stable disease (>5 months) has been seen in one patient with non-small cell lung cancer who had progressed on prior anti-PD-1 treatment. Detailed initial results from the trial to be presented at a medical conference in 1H of 2021.In May, Surface Oncology teamed up Merck to evaluate the safety and efficacy of SRF617 + Keytruda combination.Additionally, the company will initiate SRF617 combinations with gemcitabine and abraxane in pancreatic cancer, and SRF617 in combination with AB928,

For further details see:

Surface Oncology's lead cancer programs to advance to combination and expansion stages of early-stage studies